proteomic changes upon treatment with semaglutide in individuals with obesity Suboptimal therapeutic responses associated type 2 diabetes and obesity: Semaglutide as a GLP-1 Agonist:

Matching placebos were administered with identical pen-injectors

Neuroprotective effects of bee venom phospholipase A2 in the 3xTg AD mouse model of Alzheimers disease

Generally appropriate for: Adults with a BMI over 27 who want to lose weight People who have struggled with appetite control Those looking for sustainable, medically-supervised weight loss Generally not appropriate if: Pregnant or breastfeeding individuals People with a personal or family history of thyroid cancer Those with multiple endocrine neoplasia syndrome (MEN 2) Individuals with diabetic retinopathy (certain eye conditions) Common side effects: Nausea (especially at the start, usually improves) Loss of appetite (expected and therapeutic) Mild constipation or diarrhea Occasional headache or dizziness These typically subside as your body adjusts Individual results vary

This drug was created as a last resort drug for the treatment of type 2 diabetes mainly due to the side effects

Specific vendor reviews provide additional context